These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9689888)

  • 1. [Cancer of the cervix uteri: analysis of the cost-benefit and efficacy of opportunistic screening versus organized screening].
    Castronovo V; Foidart JM; Boniver J
    Rev Med Liege; 1998 May; 53(5):305-7. PubMed ID: 9689888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical cancer screening program of Paraná: cost-effective model in a developing country.
    Bleggi Torres LF; Werner B; Totsugui J; Collaço LM; Araújo SR; Huçulak M; Boza EJ; Fischer RM; De Laat L; Sobbania LC; Raggio A
    Diagn Cytopathol; 2003 Jul; 29(1):49-54. PubMed ID: 12827718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong.
    Kim JJ; Leung GM; Woo PP; Goldie SJ
    J Public Health (Oxf); 2004 Jun; 26(2):130-7. PubMed ID: 15284314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Costs and problems in cervix cancer screening are considerably underestimated].
    Bistoletti P
    Lakartidningen; 2000 Aug; 97(32-33):3506-8. PubMed ID: 11037597
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical inquiries. Should we discontinue Pap smear screening in women aged>65 years?
    Curran DR; Stigleman S; Neher JO
    J Fam Pract; 2004 Apr; 53(4):308-10. PubMed ID: 15068776
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of cervical cancer with screening programme in Branicevo District and cost-effectiveness analysis adjusted to the territory of the Republic of Serbia.
    Perovic S
    J BUON; 2009; 14(1):93-6. PubMed ID: 19373953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cervical screening in general practice: call and recall.
    Ridsdale LL
    J R Coll Gen Pract; 1987 Jun; 37(299):257-9. PubMed ID: 3129556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytological screening for cervical cancer in the province of Limburg, Belgium.
    Arbyn M; Van Nieuwenhuyse A; Bogers J; De Jonge E; De Beeck LO; Matheï C; Buntinx F
    Eur J Cancer Prev; 2011 Jan; 20(1):18-24. PubMed ID: 20805755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cervix cancer screening: results of a french team].
    Salvat J; Slamani L; Schmidt MH
    Rev Med Suisse Romande; 1997 Aug; 117(8):593-6. PubMed ID: 9340713
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cervix cancer screening can be cost-effective. Combination of vaginal smears and the HPV test should be even more beneficial].
    Bistoletti P; Ellström A; Dillner J; Sennfält K; Sparén P; Strander B
    Lakartidningen; 2005 Jun 13-26; 102(24-25):1874-6, 1878-9. PubMed ID: 16044766
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and cost-effectiveness of nationwide cervical cancer screening in Taiwan.
    Koong SL; Yen AM; Chen TH
    J Med Screen; 2006; 13 Suppl 1():S44-7. PubMed ID: 17227642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cervical cytology.
    McCrory DC; Matchar DB; Bastian L; Datta S; Hasselblad V; Hickey J; Myers E; Nanda K
    Evid Rep Technol Assess (Summ); 1999 Jan; (5):1-6. PubMed ID: 11925972
    [No Abstract]   [Full Text] [Related]  

  • 13. Cervix cancer screening in Croatia within the European Cervical Cancer Prevention Week.
    Skopljanac-Macina L; Mahovlić V; Ovanin-Rakić A; Barisić A; Rajhvajn S; Juric D; Babić D; Corusić A; Oresković S
    Coll Antropol; 2010 Jun; 34(2):613-7. PubMed ID: 20698138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity.
    Hutchinson ML; Berger BM; Farber FL
    Am J Manag Care; 2000 Jul; 6(7):766-80. PubMed ID: 11067374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost of screening for cancerous and precancerous lesions of the cervix.
    Méréa E; Le Galès C; Cochand-Priollet B; Cartier I; de Crémoux P; Vacher-Lavenu MC; Vielh P; Coste J
    Diagn Cytopathol; 2002 Oct; 27(4):251-7. PubMed ID: 12357505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The coverage of cervical screening in Hungary].
    Boncz I; Sebestyén A; Döbrossy L; Kovács A; Budai A; Székely T
    Orv Hetil; 2007 Nov; 148(46):2177-82. PubMed ID: 17988975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervical cancer in India--strategy for control.
    Prabhakar AK
    Indian J Cancer; 1992 Sep; 29(3):104-13. PubMed ID: 1292993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ["Cost-effectiveness" of cervical screening].
    Kostova P
    Akush Ginekol (Sofiia); 2007; 46(6):32-4. PubMed ID: 17974169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cost effectiveness analysis of screening strategies for cervical cancer in Tunisia].
    Lazaar HB; Aounallah-Skhiri H; Oueslati F; Frikha H; Achour N; Hsairi M
    East Mediterr Health J; 2010 Jun; 16(6):602-8. PubMed ID: 20799586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost effectiveness of human papilloma virus testing in cervical cancer screening: a literature review].
    Mejía A; Salas W
    Biomedica; 2008 Mar; 28(1):160-72. PubMed ID: 18645671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.